Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Eli Lilly and Company | Ciena | Equinix | |
|---|---|---|---|
| Moat rating | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. | narrow Ciena's FY2025 10-K describes a technology position that has held but does not lock customers in. On the durable side, the strategy is to "build on and expand our global leadership in optical networking", resting on "our proprietary WaveLogic™ coherent modem technology" and approximately 2,400 issued patents with 800 more pending as of December 2, 2025. On the limiting side, the same filing says competition "remains intense" and features "aggressive selling efforts, including using significant pricing pressure to displace incumbent vendors", that "our customer contracts generally do not include minimum or guaranteed purchases", and that "there is no assurance that we will maintain our incumbency". Concentration cuts the same way: the five largest customers contributed approximately 50% of fiscal 2025 revenue, one cloud provider approximately 18%. Its income statement reports gross profit of $1,878.9M on $4,386.5M of revenue in FY2023, $1,719.6M on $4,015.0M in FY2024 and $2,004.9M on $4,769.5M in FY2025. Self-described leadership in its segments, with customers that are re-won deal by deal, is a narrow moat. | wide The FY2025 10-K (filed 2026-02-11) grounds the advantage in an asset that took 27 years to assemble and that a competitor cannot buy: "Over our 27-year history, we have curated a diverse, industry-leading ecosystem of more than 500,000 interconnections", "over 10,500 customers, including 2,000+ network service providers and a leading market share of cloud-on ramps", across "280 data centers, in 77 markets in 36 countries", with "99.9999%+ operational uptime" delivered in 2025 and no single customer at 10% of revenue. Because the value of each IBX rises with who else is already inside it, incumbency compounds rather than decays. The counterweight is real and disclosed: Item 1A says "The global multi-tenant data center market is highly fragmented. It is estimated that we are one of more than 2,400 companies that provide these offerings around the world", and warns that competitors "may adopt aggressive pricing policies". That caps the pricing that the moat converts into, not its durability — the fragmentation sits in commodity space-and-power, while the interconnection density the filing describes has no comparable substitute. FY2025 revenue of $9.217B with operating margin recovering to 20.0% from 15.2% in FY2024 is consistent with the incumbency holding. |
| Moat type | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. | intangibles ip The FY2025 10-K locates the advantage in owned technology rather than in customer lock-in: "The success of our business and technology leadership depends significantly on our proprietary and internally developed technology." That technology is centred on WaveLogic, which Ciena's fiscal Q3 2026 earnings presentation (the source of the first two product rows below) defines as "Ciena's proprietary family of coherent optical chips — the core technology inside most of our networking products", and it reaches beyond Ciena's own systems: the 10-K's coherent pluggable transceivers use WaveLogic "for use within our systems and third-party equipment". Switching costs are the weaker candidate, because the same filing describes operators disaggregating line systems from modems and competitors using price to displace incumbents. | network effects The 10-K names the mechanism itself, twice and unprompted: "As more customers choose Equinix for high connectivity and performance reliability at the metro edge, it benefits their suppliers and business partners to colocate in the same data centers and connect directly with each other. This adjacency creates a network effect that attracts new customers while continuously enhancing our value proposition to existing customers", and in the Competitive Landscape section, "This ecosystem creates a network effect that improves performance and lowers the cost for our customers". The evidence is the count of participants rather than any patent or unit-cost claim — 500,000+ interconnections, 2,000+ network service providers, a leading share of cloud on-ramps, an Internet Exchange the filing calls "the largest global peering solution". Switching costs are a genuine second layer (fixed-duration contracts billed on space and power, physical cross connects into resident counterparties), but they are what holds a customer already inside the ecosystem; the reason to enter in the first place is who is already there. |
| Leadership | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. | co leader Slide 6 of Ciena's fiscal Q3 2026 earnings presentation of 2026-09-03 (https://s25.q4cdn.com/550667411/files/content_files/Ex-99-2-2026-Q3-Earnings-Presentation_FINAL-1.pdf) lists "#1 in Data Center Interconnect Globally" (Dell'Oro Group), "#1 in Total Optical Networking in N. America" (Cignal AI, Dell'Oro Group, Omdia) and "#1 in Submarine Networks Globally" (Omdia), with market share measured as of Q2 2026 excluding China, and a caveat that Ciena "has not independently verified" the analyst data. On the company's own presentation of that data, that is the front rank in its core segments, but the presentation does not claim the global lead in total optical networking, and the FY2025 10-K says competition is "dominated by a small number of very large, multi-national companies" - Nokia, Huawei, Cisco, Hewlett Packard Enterprise and ZTE - many of which have "substantially greater financial, operational and marketing resources, and broader product offerings". A shared front rank, led by Ciena where the company-reported rankings measure it, rather than an uncontested one. | clear leader Leadership is claimed on interconnection, not on square footage, and the filing's own evidence is about density: "our position is unmatched in the industry" is supported by 2,000+ resident network service providers, "a leading market share of cloud-on ramps", 500,000+ interconnections and an Internet Exchange described as "the largest global peering solution", across 36 countries. The band is read against neutral, ecosystem-dense colocation, where that footprint has no direct analogue. It is deliberately not read against total data centre capacity: the same 10-K puts Equinix among "more than 2,400 companies" in a "highly fragmented" MTDC market, and Item 1A concedes the company must compete for land and power against "new market entrants" drawn in by AI. |
| Pricing power | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. | moderate Moderate, and improving. The FY2025 10-K's income statement reports gross profit of $1,878.9M on $4,386.5M, $1,719.6M on $4,015.0M and $2,004.9M on $4,769.5M of revenue for FY2023-FY2025, in a market where, the filing says, rivals use "significant pricing pressure to displace incumbent vendors" and "price and total cost of ownership" heads the list of competitive factors. Since then the AI build-out has lifted gross margin: Ciena's fiscal Q3 2026 earnings presentation (https://s25.q4cdn.com/550667411/files/content_files/Ex-99-2-2026-Q3-Earnings-Presentation_FINAL-1.pdf) reports GAAP gross margin of 45.4% against 41.3% a year earlier, on revenue up 37% year over year, and guides fiscal 2027 adjusted gross margin to 45% to 46%. The presentation does not say how much of that is price rather than mix or volume, and the 10-K warns that AI-related demand has led to "a constrained supply environment" that can raise component costs. | moderate Contract structure supports price: fixed-duration agreements billed on space and power plus per-connection interconnection fees, an installed base too physically entangled to move cheaply, and 99.9999%+ uptime in 2025 as the thing being paid for. FY2025 revenue of $9.217B grew about 5% on FY2024's $8.748B while operating margin recovered to 20.0% from 15.2%, so pricing and cost were at least held. But the filing itself refuses the strong band: competitors "may adopt aggressive pricing policies, especially if they are not highly leveraged or have lower return thresholds than we do. As a result, we may suffer from pricing pressure that would adversely affect our ability to generate revenues", and some rivals bundle communications or cloud services against bare colocation. Power procurement is a further pass-through risk the filing flags. Price is defended, not dictated. |
| Summary | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." | Ciena is the optical-transport specialist among networking vendors - its fiscal Q3 2026 earnings presentation calls it "the only pure-play optical systems provider operating at scale today" - and its FY2025 10-K builds the business on one proprietary technology, the WaveLogic coherent modem, carried into the 6500 Packet-Optical Platform, Waveserver data center interconnect systems, the 6500 RLS photonic line system and coherent pluggable transceivers sold for Ciena's own systems and third-party equipment. Analyst rankings the company cites in that presentation, which it says it "has not independently verified", put Ciena first in data center interconnect globally, in total optical networking in North America and in submarine networks globally (Q2 2026, excluding China). The AI build-out has turned it into more of a cloud supplier than a telecom one: cloud providers were 53% of fiscal Q3 2026 revenue, revenue rose 37% year over year, and GAAP gross margin reached 45.4%. The 10-K is equally clear about why the position is narrow rather than wide. Competition is "dominated by a small number of very large, multi-national companies", many with greater resources; rivals use pricing to displace incumbents; contracts carry no minimum or guaranteed purchases; the five largest customers were about half of fiscal 2025 revenue; and disaggregation lets an operator buy the line system from one vendor and the modem from another, while the push into data-center interconnects brings Ciena up against Marvell, Credo and Broadcom. | Equinix is a network-neutral, multi-tenant colocation and interconnection REIT: it does not sell compute, it sells the metro-edge real estate where networks, clouds and enterprises physically meet. The FY2025 10-K describes the platform as "280 data centers, in 77 markets in 36 countries" serving "over 10,500 customers, including 2,000+ network service providers and a leading market share of cloud-on ramps", carrying "more than 500,000 interconnections" curated over 27 years, with 61% of 2025 revenue recognised outside the U.S. Revenue is structurally recurring — infrastructure offerings are "billed based on the space and power a customer consumes" under fixed-duration contracts generating MRR, interconnection is "billed based on the outbound connections from a customer" — and no customer reached 10% of 2025 revenue. AI enters the story as demand rather than as a product: the filing positions Equinix as the interconnect point for "model providers, data platforms, neoclouds and gateways", and pushes core hyperscale capacity into xScale, which is "developed and operated through our joint venture partnership arrangements". The bear case is in the company's own Item 1A. The MTDC market is "highly fragmented", Equinix being "one of more than 2,400 companies"; competitors "may adopt aggressive pricing policies"; the AI build-out invites "significant investments in the data center industry by both current competitors and new investors", after which "we could lose market share" and must "compete against certain of these competitors to secure the land and power needed for our expansion plans". Product extension has also failed before — the filing notes past offerings "have been or are being discontinued, including the Equinix Metal product". The honest reading: the interconnection ecosystem is close to unreplicable and the moat sits there; the capacity business around it is a capital race Equinix enters with scale but no immunity. |
| Chain position | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. | Ciena sits between optical-component suppliers and the operators building AI-era networks. Upstream, its FY2025 10-K says its products include "optical and electronic components for which reliable, high-volume supply is often available only from sole or limited sources", built by contract manufacturers with facilities in Canada, Mexico, Thailand, Vietnam and the United States; at November 1, 2025 it carried $826.2 million of inventory and $2.1 billion of purchase commitments. Downstream, the fiscal Q3 2026 earnings presentation puts direct cloud providers at 53% of the quarter's revenue against 37% for service providers, and describes its products as the links between data centers (data center interconnect) and between distributed AI training clusters ("scale-across"). | Equinix is the neutral meeting point of the AI and cloud supply chain rather than a link in its manufacturing path: it houses other companies' compute and sells the adjacency between them. The 10-K places it between the network layer (2,000+ service providers), the cloud layer ("a leading market share of cloud-on ramps") and enterprise consumers who "assemble these capabilities into operational stacks", and describes an AI ecosystem "of model providers, data platforms, neoclouds and gateways" curated for enterprise AI demand. Core hyperscale training capacity sits beside that, not inside it, in xScale, built with JV partners so hyperscalers "add to their core hyperscale data center deployments and existing customer access points at Equinix". The revenue is therefore levered to AI's distribution and inference edge more than to training-cluster buildout. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.13 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.38 at weight 0.20 · swarm neutral Editorial prior, not backtested. |